News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChemGenex Pharmaceuticals Limited (CXS.AX) Presents Updated Analysis at American Society of Hematology on OMAPRO(TM) in CML Patients Who Failed Two or Three Approved TKI Drugs


12/6/2010 11:13:23 AM

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced yesterday the presentation of updated clinical data showing that OMAPRO™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in a significant proportion of chronic phase chronic myeloid leukemia (CML) patients, who had failed previous attempts to control their disease with two or three FDA-approved tyrosine kinase inhibitors (TKIs). The new data were presented at the 52nd Annual American Society of Hematology Meeting in Orlando, Florida (ASH).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES